How did HAE's Q4 2024 EPS surprise impact investor confidence?

Haemonetics' (HAE) Q4 2024 EPS surprise had a positive impact on investor confidence, as evidenced by the following points:

1. **EPS Surprise Overview**: Haemonetics reported an EPS surprise of $0.01 for Q4 2024, which is a positive indicator as it indicates the company's actual performance exceeded market expectations.

|code|Ticker|Name|Date|EPS Surprise YoY|EPS Surprise|market_code|
|---|---|---|---|---|---|---|
|HAE|HAE.N|Haemonetics|20240331|314.2857142857142|0.29|169|
|HAE|HAE.N|Haemonetics|20240630|-37.5|0.1|169|
|HAE|HAE.N|Haemonetics|20240930|100|0.1|169|
|HAE|HAE.N|Haemonetics|20241231|-85.71428571428571|0.01|169|

2. **Historical Performance**: Haemonetics has a track record of exceeding earnings expectations, as seen in its Q2 2024 earnings report, where the company posted a 2.75% earnings surprise. This consistency likely bolstered investor confidence in the company's ability to perform well.
3. **Analyst Expectations**: Analysts projected an EPS of $1.09 for Q2 2024, which Haemonetics comfortably beat with an EPS of $1.12. This achievement further reinforced the company's strong financial performance and likely boosted investor confidence.
4. **Market Reaction**: The market's reaction to the earnings announcements, including a positive article on NASDAQ, suggests that investors were pleased with Haemonetics' performance. The company's stock price stability, despite a slight decrease of 2.15%, indicates a resilient investor sentiment.
5. **Future Outlook**: Haemonetics' updated FY25 earnings guidance suggests a positive outlook, which could have contributed to increased investor confidence in the company's future performance.

In conclusion, Haemonetics' Q4 2024 EPS surprise, coupled with its consistent track record of exceeding expectations and a positive market reaction, likely enhanced investor confidence in the company.